Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Indo US Bio-TechNSE:INDOUS -1.56%64 Return-on-Tangible-Asset is 5.93% as of Mar. 2026, which is 43% below its 10-year median of 10.46. GuruFocus rates NSE:INDOUS with a GF Score™ of 64/100 and a GF Value™ of ₹316.40 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 260 Agriculture companies, Indo US Bio-Tech ranks better than 86.92% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Indo US Bio-Tech's annualizedNet Income for the quarter that ended in Mar. 2026 was ₹79 Mil. Indo US Bio-Tech's average total tangible assets for the quarter that ended in Mar. 2026 was ₹1,331 Mil. Therefore, Indo US Bio-Tech's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 5.93%.
The historical rank and industry rank for Indo US Bio-Tech's Return-on-Tangible-Asset or its related term are showing as below:
NSE:INDOUS'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 3.02 Med: 10.46 Max: 17.85
Current: 11.31
During the past 13 years, Indo US Bio-Tech's highest Return-on-Tangible-Asset was 17.85%. The lowest was 3.02%. And the median was 10.46%.
NSE:INDOUS's Return-on-Tangible-Asset is ranked better than 86.92% of 260
companies
in the Agriculture industry
Industry Median: 3.44
vs NSE:INDOUS: 11.31
Indo US Bio-Tech (NSE:INDOUS) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Indo US Bio-Tech Return-on-Tangible-Asset Related Terms
Indo US Bio-Tech Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Indo US Bio-Tech's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:INDOUS vs CTVA, CF, MOS: Return-on-Tangible-Asset Comparison
For the Agricultural Inputs subindustry, Indo US Bio-Tech's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Indo US Bio-Tech Return-on-Tangible-Asset vs Agriculture Industry
For the Agriculture industry and Basic Materials sector, Indo US Bio-Tech's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Indo US Bio-Tech's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 5.93% mean?
Indo US Bio-Tech (NSE:INDOUS) has a Return-on-Tangible-Asset of 5.93% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Indo US Bio-Tech and its competitors. This is 43% below median its historical median of 10.46. Over the past decade, Indo US Bio-Tech's Return-on-Tangible-Asset has ranged from 3.02 to 17.85. According to the industry distribution chart, Indo US Bio-Tech ranks #34 out of 260 companies in the Agriculture industry, placing it in the top 13.1%.
Is Indo US Bio-Tech's Return-on-Tangible-Asset too high?
Indo US Bio-Tech's current Return-on-Tangible-Asset of 5.93% is 43% below median its 10-year median of 10.46. Over the past 10 years, this metric has ranged from a low of 3.02 to a high of 17.85. The Agriculture industry median Return-on-Tangible-Asset is 3.44. Indo US Bio-Tech's value of 5.93% is 72.4% above this industry median. Based on the distribution chart, Indo US Bio-Tech ranks #34 out of 260 companies in the Agriculture industry, which is in the top quartile — a strong position relative to peers. Overall, Indo US Bio-Tech has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Indo US Bio-Tech's Return-on-Tangible-Asset compare to CTVA and CF?
According to the Agriculture industry distribution chart, Indo US Bio-Tech ranks #34 out of 260 companies for Return-on-Tangible-Asset. This places Indo US Bio-Tech in the top 13% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 3.44. Indo US Bio-Tech's value of 5.93% is 72.4% above this benchmark. Historically, Indo US Bio-Tech's own Return-on-Tangible-Asset has ranged from 3.02 to 17.85 over the past decade. While the company's 10-year median is 10.46 vs. the industry median of 3.44, Indo US Bio-Tech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for an Agriculture company?
The median Return-on-Tangible-Asset among Agriculture companies is 3.44, based on 260 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Indo US Bio-Tech's current Return-on-Tangible-Asset of 5.93% is 72.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Indo US Bio-Tech and its competitors. For the Agriculture industry, the median Return-on-Tangible-Asset is 3.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Indo US Bio-Tech's current Return-on-Tangible-Asset is 5.93%, which is 43% below median its own 10-year median of 10.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indo US Bio-Tech stock overvalued right now?
Based on GuruFocus' analysis, Indo US Bio-Tech (NSE:INDOUS) is currently considered Possible Value Trap. The stock's GF Value™ is ₹316.40, compared to a current price of ₹81.50 — trading 74.2% below its estimated fair value. The current Return-on-Tangible-Asset is 5.93%, which is 43% below median its 10-year median of 10.46 and 72.4% above the Agriculture industry median of 3.44. Indo US Bio-Tech's overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Indo US Bio-Tech (NSE:INDOUS), the current Return-on-Tangible-Asset is 5.93% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Indo US Bio-Tech (NSE:INDOUS) Overvalued in 2026?
Based on GuruFocus' analysis, Indo US Bio-Tech stock appears to be undervalued.
The current stock price of ₹81.50 is trading 74.2% below its estimated GF Value™ of ₹316.40.
GuruFocus considers Indo US Bio-Tech to be Possible Value Trap.
Key valuation signals for NSE:INDOUS:
Return-on-Tangible-Asset: 5.93% (43% below median its 10-year median of 10.46)
GF Value™: ₹316.40 vs. price of ₹81.50 (74.2% below fair value)
Industry Position: 72.4% above the Agriculture median (#34 of 260)
No single metric tells the full story. See the NSE:INDOUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Indo US Bio-Tech Ltd is a specialized agriculture seed company. It is involved in crop research and development through breeding, production of seeds, processing, packing, and marketing of high-performing hybrid and open-pollinated varieties of crops. The company's product portfolio includes a diversified variety of agricultural seeds, namely vegetable seeds, oil seeds, pulses seeds, cereals seeds, spices seeds used in cultivating all kinds of vegetables, pulses, crops like tomato, okra, brinjal, onion, bit root, cucumber, bottle gourd, groundnut, mustard, bajra, wheat, etc.
64GF Score
Get the complete analysis for NSE:INDOUS
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INDOUS has been successfully added to your 
